NEW YORK ( TheStreet) -- C.R. Bard (NYSE: BCR) hit a new 52-week high Thursday as it traded at $95.73 compared with its previous 52-Week high of $95.72. C.R. Bard is changing hands at $95.73 with 462,047 shares traded as of 1:51 p.m. ET. Average volume has been 612,100 shares over the past 30 days. C.R. Bard has a market cap of $8.7 billion and is part of the health care sector and health services industry. Shares are up 2.8% year to date as of the close of trading on Wednesday. C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company has a P/E ratio of 16.7, below the average health services industry P/E ratio of 17.6 and below the S&P 500 P/E ratio of 23.5. TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, increase in stock price during the past year and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full C.R. Bard Ratings Report.
More from Markets
Tesla Reports Earnings on Wednesday: 3 Key Things to Watch For
The keys to Tesla's earnings report are all drivers of the company's ability to become consistently profitable.
3 Earnings Reports Will Be Key for the Market Next Week
There is a good foundation for more positive action in the week ahead.
Stocks Finish Lower, Pulled Down by Boeing, Johnson & Johnson, Weak China Growth
Stocks declined as Boeing and Johnson & Johnson pulled shares down, while China posted its weakest quarterly economic growth rate in nearly three decades, returning investors' attention to the trade talks between Washington and Beijing.